Section 1.7
Lymphoproliferative and Myeloproliferative Disorders

The JAK2(V617F) mutation may be positive in all of the following chronic myeloproliferative disorders EXCEPT:

Essential thrombocythemia Idiopathic myelofibrosis PV CML